Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction‐associated steatotic liver disease
The Journal of Pathology · 2024-09 · 264 (1) · 101-111
DOI: 10.1002/path.6330 ↗At a glance
Journal article in The Journal of Pathology, published online on 2024-07-18. Written by María Ángeles Núñez-Sánchez and 13 co-authors. Institution: Obesity, Diabetes and Metabolism Laboratory, Biomedical Research Institute of Murcia (IMIB), Murcia, Spain. Major MEDLINE topics: Putrescine, Ornithine Decarboxylase, Liver, Disease Progression. Cited 23 times so far (Crossref); 43 references. The full text is freely available in PubMed Central. Funded by: Instituto de Salud Carlos III, NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH).
Abstract (original language)
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a chronic liver condition that often progresses to more advanced stages, such as metabolic dysfunction‐associated steatohepatitis (MASH). MASH is characterized by inflammation and hepatocellular ballooning, in addition to hepatic steatosis. Despite the relatively high incidence of MASH in the population and its potential detrimental effects on human health, this liver disease is still not fully understood from a pathophysiological perspective. Deregulation of polyamine levels has been detected in various pathological conditions, including neurodegenerative diseases, inflammation, and cancer. However, the role of the polyamine pathway in chronic liver disorders such as MASLD has not been explored. In this study, we measured the expression of liver ornithine decarboxylase (ODC1), the rate‐limiting enzyme responsible for the production of putrescine, and the hepatic levels of putrescine, in a preclinical model of MASH as well as in liver biopsies of patients with obesity undergoing bariatric surgery. Our findings reveal that expression of ODC1 and the levels of putrescine, but not spermidine nor spermine, are elevated in hepatic tissue of both diet‐induced MASH mice and patients with biopsy‐proven MASH compared with control mice and patients without MASH, respectively. Furthermore, we found that the levels of putrescine were positively associated with higher aspartate aminotransferase concentrations in serum and an increased SAF score (steatosis, activity, fibrosis). Additionally, in in vitro assays using human HepG2 cells, we demonstrate that elevated levels of putrescine exacerbate the cellular response to palmitic acid, leading to decreased cell viability and increased release of CK‐18. Our results support an association between the expression of ODC1 and the progression of MASLD, which could have translational relevance in understanding the onset of this disease. © 2024 The Pathological Society of Great Britain and Ireland.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Obesity, Diabetes and Metabolism Laboratory, Biomedical Research Institute of Murcia (IMIB), Murcia, Spain.
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Illinois, Chicago, IL, USA.
- Department of Biochemistry and Molecular Biology B and Immunology, Faculty of Medicine, University of Murcia, Murcia, Spain.
- Department of General and Digestive System Surgery, Virgen de la Arrixaca University Hospital, Murcia, Spain.
- Metabolomics Platform of CEBAS-CSIC, Campus Universitario de Espinardo, Murcia, Spain.
- Experimental Pathology Platform, Biomedical Research Institute of Murcia (IMIB), Murcia, Spain.
ORCID profiles: María Ángeles Núñez-Sánchez, María Antonia Martínez-Sánchez, Marta Sierra-Cruz, Ana Lambertos, Sara Rico-Chazarra, Alba Oliva-Bolarín, Andrés Balaguer-Román, José Enrique Yuste, Carlos Manuel Martínez, Adriana Mika, José Córdoba-Chacón, Bruno Ramos-Molina
Funding
- Instituto de Salud Carlos III
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH)
- National Institutes of Health
Cite
APA
Núñez-Sánchez, M. Á., Martínez-Sánchez, M. A., Sierra-Cruz, M., Lambertos, A., Rico-Chazarra, S., Oliva-Bolarín, A., Balaguer-Román, A., Yuste, J. E., Martínez, C. M., Mika, A., Frutos, M. D., Llamoza-Torres, C. J., Córdoba-Chacón, J., & Ramos-Molina, B. (2024). Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction‐associated steatotic liver disease. The Journal of Pathology, 264(1), 101-111. https://doi.org/10.1002/path.6330
Vancouver
Núñez-Sánchez MÁ, Martínez-Sánchez MA, Sierra-Cruz M, Lambertos A, Rico-Chazarra S, Oliva-Bolarín A, et al. Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction‐associated steatotic liver disease. The Journal of Pathology. 2024;264(1):101-111. doi:10.1002/path.6330
BibTeX
@article{NezSnchez2024,
author = {Núñez-Sánchez, María Ángeles and Martínez-Sánchez, María Antonia and Sierra-Cruz, Marta and Lambertos, Ana and Rico-Chazarra, Sara and Oliva-Bolarín, Alba and Balaguer-Román, Andrés and Yuste, José Enrique and Martínez, Carlos Manuel and Mika, Adriana and Frutos, María Dolores and Llamoza-Torres, Camilo J and Córdoba-Chacón, José and Ramos-Molina, Bruno},
title = {Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction‐associated steatotic liver disease},
journal = {The Journal of Pathology},
year = {2024},
volume = {264},
number = {1},
pages = {101--111},
doi = {10.1002/path.6330}
}
EUVIMED